Memory Recovery for Alzheimer's disease

Different from the theory that misled several failures of monoclonal antibodies, ACL's timed release of brain energy prevents plaque formation at the first place. BrainGlucose and AddMem also utilized the window of opportunity during the REM sleep cycle for AD therapy. The elimination of post midnight clinical symptoms of nighmares and hallucinations has proved the effectivess and readiness of the products for further advancement to a new drug and a digital medical device.